Posts

AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

on

Henlius to Showcase 12 Research Presentations at ESMO 2026, Including U.S. Bridging Study of Serplulimab and PoC of PD-L1 ADC HLX43 in Gastric Cancer (Summary Highlights)

on

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

on

Jazz and Zymeworks' Ziihera Achieves Practice-Changing Results in Phase 3 Trial for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

on

‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure

on

Imfinzi Gains FDA Approval for Early Gastric and GEJ Cancers; BiomX Nebulizer Faces FDA Scrutiny

on

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

on

Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial

on

Ono's BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

on

Survival Benefit of Amgen's Bemarituzumab in Gastric Cancer Attenuates at Final Analysis

on

Elevation Oncology Discontinues Lead Drug and Cuts Workforce

on

Leap Therapeutics' Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials

on